Post-PCI bivalirudin infusion , as compared with no infusion , did not significantly decrease the rate of urgent target-vessel revascularization , definite stent thrombosis , or net adverse clinical events ( 11.0 % and 11.9 % , respectively ; relative risk , 0.91 ; 95 % CI , 0.74 to 1.11 ; P = 0.34 ) .